Refine by
Cancer Cells Suppliers Near Norway
211 companies found
based inSanta Clara, CALIFORNIA (USA)
Filtricine, Inc. is a clinical stage biotechnology company focused on developing novel products for cancer management. We are backed by venture capital and located in the San Francisco Bay Area of California. We are developing an innovative way to ...
Filtricine’s Innovative Technology Restricts Nutritional Support to Cancer Cells. Our strategy is to eliminate cancer cells’ access to non-essential amino acids, which ...
based inParis, FRANCE
Oncovita is a biotech company developing a disruptive virus-derived vaccine technology to treat multiple types of cancers. Our MeasovirTM platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with ...
Engineered viruses have proven to be powerful “bullets” to target cancer cells and to promote their immunogenic death. Oncolytic viruses are replicative viruses that preferentially infect tumor ...
based in, CALIFORNIA (USA)
At Delee we’re fundamentally changing not only the way cancer is detected but also how it could be treated. By developing a device capable of capturing Circulating Tumor Cells (CTCs) in a faster and more effective way than the current technologies ...
based inKerrville, TEXAS (USA)
Vitanova Biomedical, Inc. (VNB) is a San Antonio, TX-based early stage biotechnology company developing patented (pending) technology licensed from the University of Texas at San Antonio. The company’s cancer treatment, Light-Activated Intracellular ...
Vitanova Biomedical’s Cancer Therapy Technology Platform is Called Light-Activated Intracellular Acidosis (LAIA). Vitanova Biomedical (VNB) has developed a proprietary energy-based technique to elicit ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
The Dolaflexin platform was designed to increase the efficacy, safety, and tolerability of ADCs. This platform overcomes the limitations of traditional ADCs in which drugs are directly conjugated to antibodies. Dolaflexin utilizes our proprietary ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged ...
based inMunich, GERMANY
multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform for the development and clinical delivery of new cancer therapies on the basis of the founding scientists' ...
The product targets surface-bound heat shock protein 70 (Hsp70). Surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, colon, breast, pancreas. Application of mi-APO, a ...
based inVictoria, BRITISH COLUMBIA (CANADA)
Established in 2007, StressMarq Biosciences is a bioreagents company producing high quality, cutting edge research products for the life sciences and drug discovery/biopharma markets. StressMarq is a market leader in the development and ...
Product Name: c-Met Antibody (pTyr1349). Description: Rabbit Anti-Human c-Met (pTyr1349) Polyclonal. Species Reactivity: Human, Mouse, Rat. Applications: WB. Antibody Dilution: WB (1:250-1:1000); optimal dilutions for assays should be determined by ...
based inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4-1BB mAb-based, tumor antigen targeting bispecific ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
Pinaka™ is an advanced non-invasive blood test which provides therapeutically relevant information via a safe, simple and quick blood draw. Pinaka™ evaluates blood sample to detect ‘Circulating Tumor Cells’ ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ...
based inRaleigh, NORTH CAROLINA (USA)
Kaio's strategy is to develop and in-license technologies and therapies that enable the body’s own immune system to work more efficiently. The goal is to improve clinical outcomes for patients, increase the number and efficacy of therapeutic options ...
based inTucson, ARIZONA (USA)
D3Sciences is dedicated to the development of tools for improved tissue sampling to expand cancer diagnosis, therapy specificity, and research. Creating tools to improve tissue sampling for rapid, precise, and cost effective delivery of care to ...
based inAuburndale, MASSACHUSETTS (USA)
Imagin Medical, a surgical imaging company, is focusing on bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common cancer in men. It is the most expensive form of cancer to treat over the lifetime of a patient because ...
The conventional method of detecting bladder cancer uses white light during minimally invasive surgery to illuminate the bladder during a procedure called a cystoscopy. White light has been used for decades and is the ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a target. ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
During the development of the anti-glycan monoclonal antibodies (mAbs), Scancell identified unique sequence residues in the Fc region that enable mAbs to self-associate upon target recognition, resulting in more potent, high avidity ...